Riskpilot← Back to searchSign inGet full accessNMD Pharma A/S
A/SActiveCVR 36899069Palle Juul-Jensens Boulevard 82Research and experimental development on natural sciences and engineering · NACE 7210Est. 201557 employees
Revenue 2024
DKK -27,9M
+45% vs 2023
EBITDA margin
121.3%
-46% vs 2023
Equity ratio
89.8%
Financial strength
Net profit 2024
DKK -32,3M
-44% vs 2023
| Revenue | DKK -27,9M | +45% |
| EBITDA | DKK -33,8M | -46% |
| Net profit | DKK -32,3M | -44% |
| Total assets | DKK 39,4M | -15% |
| Equity | DKK 35,4M | -17% |
| Employees | 57 | — |
Legal name
NMD Pharma A/S
CVR number
36899069
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7. maj 2015
Share capital
DKK 5.497.789
Employees
57 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør, eller af bestyrelsens formand i forening med et andet bestyrelsesmedlem, eller af et bestyrelsesmedlem i forening med en direktør, eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive virksomhed med forskning og udarbejdelse af stoffer, herunder
til medicinalindustrien, samt enhver i forbindelse hermed stående virksomhed.
Address
Palle Juul-Jensens Boulevard 82
Phone
+4525518710
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -26 | -6.372 | -17.858 | -4.662 | -7.132 | -7.870 | -11.029 | -9.480 | -19.182 | -27.874 |
| Staff expenses | -0 | -2.156 | -7.762 | -1.508 | -2.013 | -2.743 | -3.224 | -3.500 | -4.040 | -5.943 |
| EBITDA | -26 | -8.528 | -25.620 | -6.170 | -9.145 | -10.613 | -14.253 | -12.980 | -23.222 | -33.817 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -19 | -36 |
| EBIT | -26 | -8.528 | -25.620 | -6.170 | -9.145 | -10.613 | -14.253 | -12.980 | -23.241 | -33.853 |
| Net financials | -1 | -47 | -1.184 | -109 | -93 | -51 | -98 | -80 | 103 | 863 |
| Profit before tax | -27 | -8.575 | -26.804 | -6.279 | -9.238 | -10.665 | -14.351 | -13.061 | -23.138 | -32.990 |
| Tax | -0 | -1.702 | -4.920 | -737 | -737 | -737 | -737 | -737 | -737 | -737 |
| Net profit | -27 | -6.873 | -21.883 | -5.543 | -8.501 | -9.928 | -13.614 | -12.324 | -22.401 | -32.254 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 32 | 14.452 | 21.339 | 6.742 | 10.065 | 11.489 | 4.920 | 27.139 | 46.393 | 39.394 |
| Equity | 23 | 13.150 | -8.734 | 5.747 | 8.211 | 9.243 | 2.596 | 25.133 | 42.673 | 35.395 |
| Long-term debt | 0 | 0 | 0 | 0 | 63 | 201 | 201 | 0 | 0 | 0 |
| Short-term debt | 9 | 1.302 | 30.073 | 995 | 1.790 | 2.044 | 2.123 | 2.006 | 3.720 | 3.999 |
| Total debt | 9 | 1.302 | 30.073 | 995 | 1.854 | 2.245 | 2.324 | 2.006 | 3.720 | 3.999 |
EBITDA margin
-3381731200.0%
This company
15.8%
Market median
-21403362125% vs market
20152024
Equity ratio
89.8%
This company
38.2%
Market median
+135% vs market
20152024
Return on equity
-91.1%
This company
18.4%
Market median
-595% vs market
20152024
Net profit margin
-3225370000.0%
This company
8.1%
Market median
-39819382816% vs market
20152024
Asset turnover
-0.71×
This company
1.12×
Market median
-163% vs market
20152024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-05-07 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PB Deputy | Deputy | 2018 | — | — |
TH Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2025 | |
Novo Holdings A/S | Company | 15.0% | 15.0% | 2023 |
| Individual | 15.0% | 15.0% | 2022 | |
LUNDBECKFOND INVEST A/S | Company | 15.0% | 15.0% | 2023 |
| Individual | 10.0% | 10.0% | 2025 | |
Styrelsen for Forskning og Uddannelse | Company | 5.0% | 5.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
NMD Pharma A/S Board members of NMD Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Paul Brian Little | Deputy | 0 companies |
| Thomas Holm Pedersen | Management | 0 companies |
| Monique Claude Schiersing | Board of Directors | 0 companies |
| Morten Døssing | Board of Directors | 0 companies |
| Fiona MacLaughlin | Board of Directors | 0 companies |
| Jeremy Paul Springhorn | Board of Directors | 0 companies |
| Michael Thomas Heffernan | Chairman | 0 companies |
| David William Evans | Board of Directors | 0 companies |
| Stephan Christgau | Board of Directors | 0 companies |
| Sabine Kohar Dandiguian | Board of Directors | 0 companies |
| Anja Ulrike DR Harmeier | Board of Directors | 0 companies |
| Christian Ellebæk Elling | Board of Directors | 0 companies |
| Simone Botti | Board of Directors | 0 companies |
| Anja Ulrike Harmeier | Board of Directors | 0 companies |
| Roel Bulthuis | Board of Directors | 0 companies |
| João Carlos Ribas de Almeida | Board of Directors | 0 companies |
| Ivan Andreevich Burkov | Board of Directors | 0 companies |
| Lucas Antoine de Breed | Board of Directors | 0 companies |
| Claus Elsborg Olesen | Board of Directors | 0 companies |
| Patrick Volkert Jozef Johannes Vink | Chairman | 0 companies |